Skip to main content

CARPL.ai Partners with Enlitic to Accelerate AI Validation for Imaging Customers

CARPL.ai Partners with Enlitic to Accelerate AI Validation for Imaging Customers

CARPL.ai and Enlitic are partnering to streamline imaging AI validation by making clinical imaging data more organized, searchable, and ready for evaluation.
CARPL.ai and Enlitic are partnering to streamline imaging AI validation by making clinical imaging data more organized, searchable, and ready for evaluation.

CUPERTINO, Calif., June 10, 2026 (GLOBE NEWSWIRE) — CARPL.ai, the world’s largest radiology AI marketplace and enterprise platform, today announced a partnership with Enlitic, to give imaging customers a stronger approach to AI validation by improving how imaging data can be used for evaluation.

Through its Ensight platform, Enlitic helps structure and normalize imaging data for AI validation workflows. For CARPL, that adds value to a platform built to help customers discover, explore, validate, and deploy imaging AI through a single environment.

This matters because one of the biggest barriers to AI adoption in addition to access to algorithms, is access to data ready for meaningful evaluation. In many healthcare organizations, imaging data is fragmented across systems, inconsistent, and difficult to search at scale. As a result, teams may spend significant time identifying the right studies and preparing data before evaluation can begin.

By helping organize imaging data earlier in the process, Enlitic Ensight supports a more efficient path to validation within the CARPL platform. That can help healthcare organizations reduce delays, compare AI solutions more effectively, and move toward deployment with greater confidence.

“Data fragmentation remains a barrier to scaling AI in radiology,” said Vidur Mahajan, CEO of CARPL.ai. “Our work with Enlitic ensures healthcare institutions can accelerate imaging AI validation with confidence before deployment, ultimately driving safer, more reliable patient care.”

“Too often, validation slows down because teams cannot quickly find and prepare the right data,” said Michael Sistenich, CEO. “By supporting CARPL with more structured and searchable imaging data, we are helping create a faster, more practical path to AI adoption.”

As healthcare organizations continue to evaluate AI more rigorously, the ability to validate earlier and more effectively will become even more important. This partnership helps CARPL offer customers a stronger way to move from AI exploration to real-world use.

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology such as MRI, CT scans, X-ray and ultrasound images and licenses such products to healthcare providers. Enlitic’s products, including its current product offering and product suite under development, seek to standardize, protect, integrate, and analyze data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

About CARPL.ai

CARPL.ai is the world’s largest radiology AI marketplace and platform offering 250+ applications from 95+ AI Partners. With regulatory clearances across multiple regions that include the FDA, CE, ANVISA, TGA and HSA, CARPL.ai provides a single user interface, a single data channel, and a single procurement channel for the discovery, testing, deployment, and monitoring of AI solutions in clinical practice. The CARPL.ai platform integrates with leading PACS systems, including Agfa HealthCare, DeepHealth, Intelerad, Philips, Ramsoft, Paxera Health, amongst others, ensuring end-to-end interoperability across imaging environments. Learn more at carpl.ai.

info@enlitic.com

+1-877-365-4842

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a3836511-f15d-4384-99e6-b5471253aaff

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.